Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
Conclusions/interpretationAbnormalities in the metabolism of intestinally derived ApoB-48-containing lipoproteins in individuals with type 2 diabetes on statins may help to explain the residual risk of CVD and may be suitable targets for interventions.Trial registrationClinicalTrials.gov NCT02948777.Graphical Abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fortamet | Heart | Metformin | Obesity | Statin Therapy | Study